(Received for publication July 12, 2002) The growing availability of sequences of bacterial genomes has revealed a number of open reading frames predicted by sequence alignment to encode antibiotic resistance proteins. The presence of these putative resistance genes within bacterial genomes raises important questions regarding potential reservoirs of resistance elements and their evolution. Here we examine four gene products encoding predicted aminoglycoside-aminocyclitol antibiotic modifying enzymes, two phosphotransferases and two acetyltransferases, derived from analysis of the genome sequence of Mycobacterium tuberculosis strain H37Rv with the goal of assigning biochemical function by purification of each protein and characterization of their ability to modify aminoglycoside antibiotics. Only one of these enzymes, the previously characterized aminoglycoside acetyltransferase AAC(2')-Ic, displayed compelling aminoglycoside modifying The sequencing of numerous microbial genomes in recent years has opened up many new avenues of research, with contributions from various scientific disciplines and the application of various new technologies to aid in genome analysis (reviewed in1,2). An unexpected outcome of the availability of this sequence data is the prevalence of predicted antibiotic resistance genes within the genomes of many bacteria and archae as annotated by sequence similarity. While chromosomally encoded resistance elements have been previously associated with certain bacterial species, e.g. in the Acinetobacter genus, the preponderance of antibiotic resistance genes have been linked to mobile genetics elements such as plasmids, transposons and integrons. The number of genetic elements emerging from whole genome sequence analysis is therefore of significance to our understanding of the origins of antibiotic resistance and its ecology.
A case in point is the genomic data from various mycobacterial species. These organisms include the causative agents of some of the most deadly infectious diseases and antibiotic treatment is complex and increasingly difficult as multidrug resistant strains of, for example, Mycobacterium tuberculosis emerge. The genomes of three mycobacteria have been sequenced: M. tuberculosis H37Rv, a laboratory stain of the organism that causes tuberculosis, M. tuberculosis CDC1551 (http://www.tigr.org/), a multi-drug resistant strain, and Mycobacterium leprae4), the causative agent of leprosy. These bacteria show several potential antibiotic resistance genes within their genomes including aminoglycoside resistance elements (Table 1) .
Resistance to the aminoglycoside class of antibiotics is prevalent in both Gram-positive and Gram-negative bacteria and is most commonly caused by enzymes that modify the drugs by either O-phosphorylation or Nacetylation (for review see reference 5). In mycobacteria, aminoglycoside acetyltransferase activity has been detected in isolates of M. chelonei, M. kansasii, M. phlei, M. smegmatis and M. vaccae6-10) and phosphotransferase activity has been detected in M. fortuitum9), although in many cases enzymatic activity did not correlate with observed resistance. The aminoglycoside 2'-N-acetyltransferase gene, aac(2')-Ic from M. tuberculosis H37Rv Analysis of the complete genome sequence of M. tuberculosis H37Rv13) identified several genes encoding putative aminoglycoside modifying enzymes in addition to the known aac(2')-Ic, including two putative phosphotransferases Rv3817, and Rv3225c, and one possible acetyltransferase Rv1347c. The Rv3817 gene product shows homology to several aminoglycoside phosphotransferases found in a variety of bacteria, including type V APH(3') enzymes from neomycin-producing Streptomyces fradiae and Micromonospora chalcea14,15) as well as a type II APH(3') protein from Pseudomonas aeruginosa16).
Similarly, the second larger putative APH protein, Rv3225c, is homologous to a type I 3'-phosphotransferase from Escherichia coli17). The third and final putative resistance protein, a potential aminoglycoside acetyltransferase, Rv1347c, shares homology with a Pseudomonas aeruginosa type II aminoglycoside N-6'-acetyltransferase18) as well as with a Type I AAC from Serratia sp.19) and to the C-terminal portion of a bacterial malonyl-CoA decarboxylase20).
The claim of aminoglycoside resistance suggested by in silico analysis of gene sequences requires biochemical evidence for validation, i.e. functional annotation. This study describes the characterization of putative aminoglycoside modifying enzymes from M. tuberculosis by overexpression in E. coli, purification, and enzymatic assay for aminoglycoside modification activity. We demonstrate that only the known aminoglycoside acetyltransferase AAC(2')-Ic is a bona fide antibiotic resistance element.
Materials and Methods

General Materials
Assay reagents and antibiotics were from Sigma (St.
Louis, MO, USA), with the exception of kanamycin and gentamicin, which were purchased from Bioshop 
Subcloning of Putative Aminoglycoside Modifying Enzymes
Cosmid DNA containing the genes for the putative aminoglycoside modifying enzymes Rv3225c, Rv3817c, and Rv1347c was provided by Dr. S. COLE at the Institut Pasteur. The two putative phosphotransferase genes were amplified from purified cosmid DNA using the following oligonucleotides: for Rv3225c, 5'-CGGAATTCATATGC-GCTTTG CGAAGCTGTCCG-3' and 5'-CGGAATTCAA-GCTTCTAACATCCGGGC CTAGCGCC-3' and for Rv3817, 5'-CGGAATTCATATGTCCTTCCCCTCATCGC-3' and Purification of the hexahistidine tagged putative phosphotransferase proteins followed the procedure that we have previously used to purify HisAAC(6')-APH(2") using Purification of the hexahistidine tagged Rv1347c protein followed the same general procedure, using 50mM HEPES pH 7.5, 500mM NaCl and 20mM imidazole, 1mM EDTA, 0.1mM DTT, and 1mM phenylmethanesulfonyl fluoride as lysis buffer, 50mM HEPES pH 7.5, 500mM NaCl and 20mM imidazole as equilibration buffer, and a 0% to 50% linear gradient of 50mM HEPES pH 7.5, 500mM NaCl, and 250mM imidazole for elution of HisRv1347c. Pure protein was pooled and dialyzed against 25mM HEPES pH 7.5 and 2mM EDTA.
AAC(2')-Ic was purified as previously described12).
Aminoglycoside Phosphotransferase Assays Aminoglycoside kinase activity was assessed by using the PK/LDH assay described previously23), with reactions microtitre plate format using a SpectraMAX PLUS spectrophotometer (Molecular Devices). The observed ATPase activity of HisRv3817 allowed us to determine Michaelis-Menten kinetics by a fit of collected data by nonlinear least fit squares to Eq. 1, using Grafit version 4.024):
The potential for low level aminoglycoside kinase activity was assessed by using the 32P ATP phosphocellulose binding assay described previously23).
Protein Kinase and Autophosphorylation Assays
We also tested the enzymes for the potential to histones type VIII-S, deoxyribonuclease, ribonuclease, MBP, lysozyme, lactic acid dehydrogenase, and APH(3')-IIIa, using the procedure outlined previously25). The acetylation of H3/H4 histones by AAC(6')-Ii as described25) served as positive control.
Malonyl-CoA Decarboxylase Assays
Since the Rv1347c gene product also exhibits sequence homology to the C-terminal portion of a bacterial malonylCoA decarboxylase, we investigated the possibility that this protein may decarboxylate malonyl-CoA to produce CO2 and acetyl-CoA. We therefore used a spectrophotometric assay to monitor the possible formation of acetyl-CoA by Rv1347c by coupling it to aminoglycoside acetylation by AAC(6')-Ii. We also used reverse-phase HPLC to monitor any acetyl-CoA production and to confirm that HisRv1347c number of aminoglycosides using standard methods27).
Results
Protein Purification
Overexpression of the putative aminoglycoside phosphotransferase and acetyltransferase enzymes in E. coli allowed us to obtain reasonable quantities of protein for purification and subsequent characterization. We ultimately utilized the His-tagged versions of all three proteins to ease purification, with subsequent overexpression and purification over Ni NTA agarose resulting in highly purified HisRv3817, HisRv3225c and HisRv1347c proteins (Fig. 1) .
This facilitated the investigation of these proteins as potential resistance enzymes, as described below.
Aminoglycoside Phosphotransferase Screens
HisRv3817 and HisRv3225c were first tested for the ability to phosphorylate a number of aminoglycosides by using the standard spectrophotometric PK/LDH assay.
Although a large variety of aminoglycosides were tested, including representatives of all three classes of aminoglycosides, we were unable to detect any significant aminoglycoside kinase activity for either protein. We were, however, able to monitor significant ATP hydrolysis by both enzymes, where we determined HisRv3817 to have a KM of hydrolysis. Thus, both proteins bind ATP and have low levels of ATPase activity.
As it was possible that the enzymes could modify aminoglycosides at very low levels that were masked by the level of ATP hydrolysis, we re-screened the aminoglycoside substrates using the more sensitive 32P-ATP phosphocellulose binding assay. Using this method, we were able to monitor very minor aminoglycoside phosphorylation by HisRv3225c, although this activity was several hundredfold lower than the activity observed for a typical aminoglycoside kinase, such as the enterococcal APH(2')-la protein used as a positive control in these studies. Aminoglycoside Acetyltransferase Screens
We were unable to detect aminoglycoside acetyltransferase activity towards the aminoglycosides and other antibiotics tested, using either the CoA spectrophotometric titration assay or a more sensitive radioactive [14C]acetylCoA phosphocellulose binding assay. On the other hand, AAC(2')-Ic, did show robust activity towards a number of aminoglycosides, as expected. MIC determinations and filter disk assays were consistent with these results, which indicated that no antibiotic resistance was conferred by the Rv1347c protein. Taken together, these results demonstrate that Rv1347c does not behave as an aminoglycoside or other antibiotic acetyltransferase enzyme both in vitro and in vivo.
Additional Screens of Potential Rv1347c Activities
Since Rv1347c also shows homology to the C-terminal region of a bacterial malonyl-CoA decarboxylase, we investigated whether this protein possesses decarboxylation activity. We did not detect any generation of acetyl-CoA upon incubation of the enzyme with malonyl-CoA and reverse-phase HPLC analysis confirmed that malonyl-CoA was not a substrate for Rv1347c.
As many aminoglycoside acetyltransferases are structurally similar to eukaryotic protein acetyltransferases and in some cases even demonstrate functional homology25), we investigated whether Rv1347c could acetylate proteins. We screened various proteins as potential acetyl group acceptors and found that Rv1347c did not modify any of the proteins tested, suggesting that it does not function as a protein acetyltransferase.
To further investigate the possible function of this protein, we followed up on the observation that a low level of acetyl- phosphatases. Representative substrates of the common subclasses of kinases also failed to show significant activity.
Therefore the true role of these enzymes remains a mystery. Unlike the Rv1347c thioesterase, their positioning within the genome reveals no obvious clues to their activity. The results of this study have demonstrated that the putative aminoglycoside modifying enzymes Rv1374c, Rv3817c and Rv3225c do not behave as antibiotic resistance enzymes under our experimental conditions, and that AAC(2')-Ic does demonstrate the predicted activity as previously shown. These results reinforce the necessity of biochemical assays to follow up the in silico annotation phase of microbial genome analysis. More importantly however, the analysis of these proteins reveals the large number of microbial genes with the capacity to evolve into resistance elements. All of the gene products studied bound the appropriate cosubstrates acylCoA or ATP as evidenced by their catalytic properties (thioesterase or ATPase). While somewhat paradoxically, aminoglycoside resistance in M. tuberculosis seems to be exclusively the result of target ribosomal mutations30,31). The modest activity of these gene products suggests the potential for selection of the emergence of upregulated AAC(2')-Ic production (analogous to the P. stuartii phenomenon32)) or altered Rv3225c with increased aminoglycoside kinase activity resulting in resistance. This potential, embedded in the genetic background of this organism should be considered when alternate therapies for infection are considered that may involve aminoglycoside use.
